ImpediMed announces increased payor coverage for lymphedema assessment

ImpediMed Limited (ASX:IPD) has announced that Emblem Health and Presbyterian Health have updated their medical policies to include positive coverage for the use of Bioimpedance Spectroscopy (BIS) for lymphedema assessment. This update has resulted in a total covered lives increase to 144 million, with 16 states now at Critical Mass (>80% covered lives).

ImpediMed CEO Dr Bains comments on the company's commercial progress

We are pleased to see growing coverage, and the achievement of medically necessary status supports the ability of patients across the U.S. to access early lymphoedema screening.

Summary of ImpediMed's announcement and outlook

ImpediMed (ASX:IPD) has announced an expansion in payor coverage for lymphedema assessment, with Emblem Health and Presbyterian Health updating their medical policies to include positive coverage for Bioimpedance Spectroscopy. This update has resulted in a total covered lives increase to 144 million, with 16 states now at Critical Mass (>80% covered lives). The company's CEO, Dr Bains, expressed satisfaction with the growing coverage and highlighted the achievement of medically necessary status, which supports patients' access to early lymphoedema screening. ImpediMed's focus on maximising patient health through its bioimpedance spectroscopy (BIS) technology and the FDA-cleared SOZO Digital Health Platform positions the company for continued strong growth in the lymphoedema market.